False-positive screening results in the Finnish prostate cancer screening trial. - Wikidata - awgldk - TriplyDB

False-positive screening results in the Finnish prostate cancer screening trial.

False-positive screening results in the Finnish prostate cancer screening trial.

http://www.wikidata.org/entity/Q42914714

about

Screening for prostate cancer Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease - the 2001-2008 National Health and Nutrition Examination Survey.Furthering the prostate cancer screening debate (prostate cancer specific mortality and associated risks).Risk perception and psychological morbidity in men at elevated risk for prostate cancer Molecular Form Differences Between Prostate-Specific Antigen (PSA) Standards Create Quantitative Discordances in PSA ELISA Measurements.The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States.Perspective on diagnostics for global health Identification of biomarkers for colorectal cancer through proteomics-based approaches.Evaluation of Combined Quantification of PCA3 and AMACR Gene Expression for Molecular Diagnosis of Prostate Cancer in Moroccan Patients by RT-qPCR Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.Development of Adenosine Deaminase-Specific IgY Antibodies: Diagnostic and Inhibitory Application.

P2860

Q24201690-2EDB753F-DFAF-4E17-AD6C-CB55E796D9A0 Q26767044-15D951B6-A757-422D-A0DF-3FEDEC8079F8 Q26781093-8A4D6B1F-287C-4535-AA1A-E47C1B0F3810 Q35236584-C640201D-6131-4565-8F0E-17B1CFE02A20 Q35605735-8255D52C-6844-495C-9AA2-20BF21A640A0 Q36394622-680746ED-896C-4E50-81F5-65AD982DBD35 Q36616932-56C41273-1D34-4B15-860E-B4CEFBA1F5FA Q36686892-A9F47530-440D-481E-ABDF-1B313BBEEECB Q37092106-6C27F388-162A-4C4E-AE94-9C2794F05CB3 Q37818315-37628B71-920F-4F24-8142-C10565D77C1A Q38997193-82824158-1664-42E2-9C6D-6A5CA6C32624 Q40116383-EA9303A1-01CE-4587-B09A-7E25E3544A98 Q50086400-D7F5D362-1D6A-40FD-BBF2-8F48A9A58706

P2860

False-positive screening results in the Finnish prostate cancer screening trial.

http://www.wikidata.org/entity/Q42914714

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

False-positive screening results in the Finnish prostate cancer screening trial.

@en

False-positive screening results in the Finnish prostate cancer screening trial.

@nl

type

label

False-positive screening results in the Finnish prostate cancer screening trial.

@en

False-positive screening results in the Finnish prostate cancer screening trial.

@nl

prefLabel

False-positive screening results in the Finnish prostate cancer screening trial.

@en

False-positive screening results in the Finnish prostate cancer screening trial.

@nl

P1433

Q42914714-533494CD-3756-438B-AF69-BAB87BE1721A

P1476

Q42914714-F2AC42C5-76D0-45EC-A0D8-27D4BEDFD2BE

P2093

Q42914714-261E29FD-234B-4733-9ED7-0112F822B0D3

Q42914714-61A8800E-C009-4754-888B-B99732E17834

Q42914714-74B3409A-F4D9-429E-A1D1-ADBE8CE6161C

Q42914714-99C076D6-ECDD-4FB6-B252-93277362F952

Q42914714-A19A1FCE-4BB9-4579-9E79-30AEB42B8471

Q42914714-BE8B445B-B36A-4390-B0C9-D8B1A3BB3D5F

Q42914714-CC4DBECC-AECD-4487-A35D-2A16F8638B43

P2860

Q42914714-1CAEF712-CE74-4308-8F30-DAA5367FCC11

Q42914714-23BB9CC7-E316-4749-92F9-AADAB9AF236F

Q42914714-25DA47A6-B267-4907-8E6A-CB202D5E4007

Q42914714-70DD6992-00DD-45BA-9072-463F6C5E63C4

Q42914714-7FA1088B-00AD-40C8-8F5F-823560D40807

Q42914714-825105EB-709B-4849-87C8-6C028A55AD11

Q42914714-93ED72A6-BB46-417A-8848-72F03A524DFE

Q42914714-98F4A53B-F8E2-462B-A175-F129CFAF2533

Q42914714-A9D94011-8255-4A5B-A632-14E790C1AA96

Q42914714-B979D71C-9627-42F1-8E71-26F317FC1C82

P2888

Q42914714-A8FCC32F-1C83-4914-99AC-3E637A95AD0C

P304

Q42914714-BA70FC92-961A-404F-B6FA-9C9836F8FB7C

P31

Q42914714-77892A61-6721-41EF-8E62-F6308033AE46

P356

Q42914714-6308C3F3-7A14-408E-BF8A-601860008FE0

P407

Q42914714-F7D2B096-A336-4C95-B254-4DB15B9BC26C

P433

Q42914714-2161E595-835C-4E7D-9440-EAFDBDE4716A

P478

Q42914714-C088A142-6E77-482C-B15E-FC12A8AEFF36

P50

Q42914714-7C71973E-7C21-40A2-AED2-08842BAEA25F

P577

Q42914714-2BAAE01C-FAC2-4FD9-9727-95980F14B6E8

P5875

Q42914714-43AFC01F-C749-4D65-BF47-F7B322FB5171

P6179

Q42914714-75045B59-2C7D-470C-B3CE-749579A8ED5D

P698

Q42914714-D27F7FFD-0103-4996-8E2F-D8933F9DF7A2

P921

Q42914714-0985DC3B-DBD9-45F6-A92D-4EA3134479E2

P932

Q42914714-F388F2EC-7548-42F6-BB6E-7872E29FD1B1

P356

P1433

British Journal of Cancer

P1476

False-positive screening results in the Finnish prostate cancer screening trial.

@en

P2093

L Määttänen

http://www.w3.org/2001/XMLSchema#string

M Ala-Opas

http://www.w3.org/2001/XMLSchema#string

P Kujala

http://www.w3.org/2001/XMLSchema#string

T J Murtola

http://www.w3.org/2001/XMLSchema#string

T L J Tammela

http://www.w3.org/2001/XMLSchema#string

T P Kilpeläinen

http://www.w3.org/2001/XMLSchema#string

U-H Stenman

http://www.w3.org/2001/XMLSchema#string

P2860

Mortality results from a randomized prostate-cancer screening trial

Cumulative incidence of false-positive results in repeated, multimodal cancer screening

Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005

Global cancer statistics, 2002

Screening and prostate-cancer mortality in a randomized European study

Prostate-specific antigen and other prostate cancer markers.

Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

When to biopsy and when to stop biopsying.

The impact of a suspicious prostate biopsy on patients' psychological, socio-behavioral, and medical care outcomes.

P2888

P304

469-474

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605512

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40850774

http://www.w3.org/2001/XMLSchema#string

P6179

1047895734

http://www.w3.org/2001/XMLSchema#string

P698

20051951

http://www.w3.org/2001/XMLSchema#string

P921

P932

2822946

http://www.w3.org/2001/XMLSchema#string